AKBA
Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. (AKBA) has 8 SEC Form 4 filings (8 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jul 1, 2026.
- Industry:Biotechnology
- CEO:John Butler
- Employees:194
- HQ:Cambridge, MA, US
- IPO:2014-03-20
Insider Buying
$87K
reported purchases (SEC code P)
Insider Selling
$62K
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$244.1M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Ostrowski ErikFirst filing | SVP, CFO, CBO & Treasurer | Sale | 56,019 | $62K | Jul 1 | SEC ↗ |
Butler John P.First filing | CEO and President | Purchase | 69,270 | $87K | Mar 5 | SEC ↗ |
Related companies
Akebia Therapeutics, Inc. is in the Healthcare sector.